Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07480941 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma(DUAL-CAR-NK-GB) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03749187 | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas(PNOC017) | active not recruiting | Phase 1 | 78 | University of California, San FranciscoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | not yet recruiting | Phase 1 | 40 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06917885 | CUE-102 in Recurrent Glioblastoma | recruiting | Phase 1 | 18 | David Reardon, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | completed | Phase 1 | 37 | CureVacINDUSTRY | 3 | Feb 18, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | active not recruiting | Phase 1 | 63 | Patrick Wen, MDOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07218367 | Phase I Trial of pH Resections of GBM at VA | not yet recruiting | Phase 1 | 12 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03681028 | Feasibility of Individualized Therapy for Recurrent Glioblastoma | completed | Phase 1 | 30 | Jennifer ClarkeOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | active not recruiting | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | not yet recruiting | Phase 1 | 8 | Jennifer LeddonOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04216329 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | recruiting | Phase 1 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07193628 | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma | recruiting | Phase 1 | 14 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 25, 2026source: clinicaltrials